PhageLab

PhageLab® is an AI-powered biotech platform focused on combating the global bacterial threat.

Our solution, highlighted in a reputable scientific journal, shows high efficacy in targeting Salmonella.

Antibiotics are becoming ineffective, leading to an imminent global health catastrophe. Meat consumption continues to grow, reliant heavily on antibiotics, while Big Pharma is backing away from new antibiotic development.

The antibacterial resistance issue creates a significant, growing market ready for disruption, valued at $104 billion.

PhageLab offers a fast, safe, and effective solution using bacteriophages, nature's way of fighting bacteria. Our platform customizes solutions within 45 days.

Our patented epidemiological analysis algorithm and extensive repositories offer unmatched data and capabilities.

PhageLab has showcased efficacy in field trials, eliminating up to 100% of Salmonella presence.

Our diverse team of nearly 100 people operates out of LATAM and the EU, led by experienced founders and executives with extensive industry experience.

With ineffective antibiotics, the world faces a dire MDR threat. PhageLab provides a scalable, effective solution to disrupt a $104B market using phages and advanced AI.

Science works and we can prove it.

Learn more about our process, lab, and the antibiotic crisis.